Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management

  • Treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia (Ph+ ALL) has been revolutionized with the advent of tyrosine kinase inhibitors (TKIs). Most patients with CML achieve long-term survival similar to individuals without CML due to treatment with TKIs not only in frontline but also in further lines of therapy. The third-generation TKI ponatinib has demonstrated efficacy in patients with refractory CML and Ph+ ALL. Ponatinib is currently the most potent TKI in this setting demonstrating activity against T315I mutant clones. However, ponatinib’s safety data revealed a dose-dependent, increased risk of serious cardiovascular (CV) events. Guidance is needed to evaluate the benefit–risk profile of TKIs, such as ponatinib, and safety measures to prevent treatment-associated CV events. An expert panel of German hematologists and cardiologists summarize current evidence regarding ponatinib’s efficacy and CV safety profile. We propose CV management strategies for patients who are candidates for ponatinib.

Download full text files

Export metadata

Metadaten
Author:Susanne Saußele, Wilhelm Haverkamp, Fabian Lang, Steffen KoschmiederORCiDGND, Alexander Kiani, Kathleen Jentsch-Ullrich, Frank Stegelmann, Heike Pfeifer, Paul La Rosée, Nicola GökbugetGND, Christina Rieger, Cornelius WallerORCiDGND, Georg-Nikolaus Franke, Philipp Le Coutre, Rudolf Kirchmair, Christian Junghanß
URN:urn:nbn:de:hebis:30:3-624068
DOI:https://doi.org/10.1159/000501927
ISSN:1421-9662
Parent Title (English):Acta haematologica
Publisher:Karger
Place of publication:Basel
Document Type:Article
Language:English
Date of Publication (online):2019/10/07
Date of first Publication:2019/10/07
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2021/08/18
Tag:Philadelphia chromosome-positive acute leukemia; Ponatinib; cardiovascular management; chronic myeloid leukemia; consensus paper; tyrosine kinase inhibitor
Volume:143
Issue:3
Page Number:15
First Page:217
Last Page:231
HeBIS-PPN:486227871
Institutes:Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung-Nicht kommerziell - Keine Bearbeitung 4.0